Literature DB >> 33909487

Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis.

Ryuji Yasumatsu1, Tomomi Manako1, Rina Jiromaru1, Kazuki Hashimoto1, Takahiro Wakasaki1, Mioko Matsuo1, Takashi Nakagawa1.   

Abstract

OBJECTIVE: Early detection of hypopharyngeal squamous cell carcinoma (SCC) is important for both an improved prognosis and less-invasive treatment. We retrospectively analyzed the detection rates of early hypopharyngeal SCCs according to the evaluation methods and the clinical management of early hypopharyngeal SCCs.
METHODS: Sixty-eight patients with early hypopharyngeal SCC who were diagnosed were reviewed.
RESULTS: The number of early hypopharyngeal cancer patients with asymptomatic or synchronous or metachronous esophageal cancer examined by upper gastrointestinal endoscopy with narrow-band imaging (NBI) was significantly higher than those examined by laryngopharyngeal endoscopy with NBI. The 3-year disease-specific survival rates according to T classification were as follows: Tis, 100%; T1, 100%; T2, 79.8%; and overall, 91.2%, respectively.
CONCLUSIONS: Early-stage hypopharyngeal SCC can be cured by minimally invasive transoral surgery or radiotherapy. Observation of the pharynx using NBI in patients with a history of head and neck cancer, esophageal cancer, gastric cancer, or pharyngeal discomfort is very important, and routinely examining the pharynx with NBI, even in patients undergoing endoscopy for screening purposes, is recommended.

Entities:  

Keywords:  early stage; esophagus; high resolution; hypopharynx; squamous cell carcinoma

Year:  2021        PMID: 33909487     DOI: 10.1177/01455613211013084

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  1 in total

1.  Postoperative Examination of Laryngeal Malignant Tumor Based on Narrowband Imaging Resolution Enhancement Technology.

Authors:  Neng Yang; Chenchen Zhao; Fenfen Lin; Jiaojiao Wu; Ben Liu
Journal:  Contrast Media Mol Imaging       Date:  2022-05-28       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.